within Pharmacolibrary.Drugs.ATC.C;

model C08DA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 0.02,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015000000000000001,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0022,
    k12             = 85,
    k21             = 85
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08DA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gallopamil is a calcium channel blocker of the phenylalkylamine class, chemically related to verapamil. It was previously used for the treatment of angina pectoris and certain cardiac arrhythmias. However, it is not widely approved nor commonly used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Parameters estimated for adult healthy volunteers; no recent or original clinical PK studies directly cited in literature, parameters based on older references and secondary review sources.</p><h4>References</h4><ol><li><p>Gross, AS, et al., &amp; Eichelbaum, M (1997). Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil. <i>The Journal of pharmacology and experimental therapeutics</i> 281(3) 1102–1112. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9190842/\">https://pubmed.ncbi.nlm.nih.gov/9190842</a></p></li><li><p>Gross, AS, et al., &amp; Mikus, G (2000). Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. <i>British journal of clinical pharmacology</i> 49(2) 132–138. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2000.00115.x\">10.1046/j.1365-2125.2000.00115.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10671907/\">https://pubmed.ncbi.nlm.nih.gov/10671907</a></p></li><li><p>Ferrara, N, et al., &amp; Rengo, F (1996). Efficacy and pharmacokinetics of gallopamil in patients with coronary artery disease. <i>Pharmacological research</i> 34(1-2) 37–41. DOI:<a href=\"https://doi.org/10.1006/phrs.1996.0061\">10.1006/phrs.1996.0061</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8981554/\">https://pubmed.ncbi.nlm.nih.gov/8981554</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08DA02;
